Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes

IF 3.2 3区医学

Journal of Diabetes Investigation Pub Date : 2023-04-20 DOI:10.1111/jdi.14016

Nobuaki Takehana, Tomoyasu Fukui, Yusaku Mori, Munenori Hiromura, Michishige Terasaki, Makoto Ohara, Michiya Takada, Masako Tomoyasu, Yoshihisa Ito, Tetsuro Kobayashi, Sho-ichi Yamagishi

{"title":"Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes","authors":"Nobuaki Takehana, Tomoyasu Fukui, Yusaku Mori, Munenori Hiromura, Michishige Terasaki, Makoto Ohara, Michiya Takada, Masako Tomoyasu, Yoshihisa Ito, Tetsuro Kobayashi, Sho-ichi Yamagishi","doi":"10.1111/jdi.14016","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims/Introduction</h3>\n \n <p>This study aimed to compare the positivity rates of glutamic acid decarboxylase autoantibodies (GADA) and ElisaRSR™ 3 Screen ICA™ (3 Screen ICA), a newly developed assay for the simultaneous measurement of GADA, insulinoma-associated antigen-2 autoantibodies (IA-2A), and zinc transporter 8 autoantibodies (ZnT8A), in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes (SPIDDM).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We enrolled 53 patients with SPIDDM who were positive for GADA at the diagnosis and 98 non-diabetic individuals, and investigated the diagnostic accuracy of the 3 Screen ICA (cutoff index ≥30 units) compared with that of GADA. In addition, we compared the clinical characteristics of patients with SPIDDM who were negative or positive on 3 Screen ICA.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The positivity rates of 3 Screen ICA, GADA, IA-2A, and ZnT8A were 88.7, 86.8, 24.5, and 13.2%, respectively. The respective sensitivity, specificity, and positive and negative predictive values for SPIDDM were 88.7, 100, 100, and 94.2% by 3 Screen ICA and 86.8, 100, 100.0, and 93.3% by GADA. There were no significant differences in age at onset, duration of diabetes, body mass index, glycated hemoglobin and C-peptide levels, and the prevalence of autoimmune thyroiditis between patients with SPIDDM who were positive or negative on 3 Screen ICA. However, the prevalence of insulin users was significantly higher in those who were positive than in those who were negative on 3 Screen ICA.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Similar to GADA, 3 Screen ICA may be a useful diagnostic tool for detecting patients with SPIDDM.</p>\n </section>\n </div>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 7","pages":"856-863"},"PeriodicalIF":3.2000,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14016","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.14016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Aims/Introduction

This study aimed to compare the positivity rates of glutamic acid decarboxylase autoantibodies (GADA) and ElisaRSR™ 3 Screen ICA™ (3 Screen ICA), a newly developed assay for the simultaneous measurement of GADA, insulinoma-associated antigen-2 autoantibodies (IA-2A), and zinc transporter 8 autoantibodies (ZnT8A), in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes (SPIDDM).

Materials and Methods

We enrolled 53 patients with SPIDDM who were positive for GADA at the diagnosis and 98 non-diabetic individuals, and investigated the diagnostic accuracy of the 3 Screen ICA (cutoff index ≥30 units) compared with that of GADA. In addition, we compared the clinical characteristics of patients with SPIDDM who were negative or positive on 3 Screen ICA.

Results

The positivity rates of 3 Screen ICA, GADA, IA-2A, and ZnT8A were 88.7, 86.8, 24.5, and 13.2%, respectively. The respective sensitivity, specificity, and positive and negative predictive values for SPIDDM were 88.7, 100, 100, and 94.2% by 3 Screen ICA and 86.8, 100, 100.0, and 93.3% by GADA. There were no significant differences in age at onset, duration of diabetes, body mass index, glycated hemoglobin and C-peptide levels, and the prevalence of autoimmune thyroiditis between patients with SPIDDM who were positive or negative on 3 Screen ICA. However, the prevalence of insulin users was significantly higher in those who were positive than in those who were negative on 3 Screen ICA.

Conclusions

Similar to GADA, 3 Screen ICA may be a useful diagnostic tool for detecting patients with SPIDDM.

Abstract Image

查看原文本刊更多论文

谷氨酸脱羧酶抗体与ElisaRSR™3 Screen ICA™在新近获得的慢进展型糖尿病患者血清中的阳性率比较

本研究旨在比较谷氨酸脱羧酶自身抗体(GADA)和ElisaRSR™3 Screen ICA™(3 Screen ICA)的阳性率，ElisaRSR™3 Screen ICA是一种新开发的同时测量GADA、胰岛素瘤相关抗原-2自身抗体(IA-2A)和锌转运蛋白8自身抗体(ZnT8A)的检测方法。在最近获得的先前诊断为缓慢进展型1型糖尿病(SPIDDM)患者的血清中。材料与方法入选53例确诊为GADA阳性的SPIDDM患者和98例非糖尿病患者，比较3 Screen ICA(截止指数≥30单位)与GADA的诊断准确性。此外，我们比较了3 Screen ICA阴性和阳性的SPIDDM患者的临床特征。结果Screen ICA、GADA、IA-2A和ZnT8A的阳性率分别为88.7、86.8、24.5和13.2%。3 Screen ICA对SPIDDM的敏感性、特异性和阳性、阴性预测值分别为88.7、100、100和94.2%，GADA为86.8、100、100.0和93.3%。3 Screen ICA阳性和阴性的SPIDDM患者在发病年龄、糖尿病病程、体重指数、糖化血红蛋白和c肽水平以及自身免疫性甲状腺炎患病率方面无显著差异。然而，胰岛素使用者的流行率在3 Screen ICA阳性人群中明显高于阴性人群。结论与GADA类似，3 Screen ICA可能是检测SPIDDM患者的有效诊断工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation Medicine-Internal Medicine

自引率

9.40%

发文量

218

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).